Bing

SEARCH HISTORY

Investors in Spectrum Pharmaceuticals Inc (SPPI) saw new options begin trading this week, for the September 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SPPI
The Street · 7/21/2015
The stock should find initial support at its 50-day moving average (MA) of $6.84 and further support at its 200-day MA of $6.78. Spectrum Pharmaceuticals Inc. develops in-licensed drugs for the treatment and supportive care of cancer patients. The Company ...
Financial News Network Online · ByRobert Cotter · 7/29/2015
Over the last 30 days, the company witnessed two negative estimate revisions and the Zacks Consensus Estimate also moved lower, signaling trouble down the road. So make sure to keep an eye on this stock going forward to see if yesterday’s move …
ZACKS · 5/13/2015
More from Bing News
Small cap cancer stock Spectrum Pharmaceuticals, Inc (NASDAQ: SPPI), who’s performance benchmarks in the cancer space include mid cap Juno Therapeutics Inc (NASDAQ: JUNO) and small cap Merrimack Pharmaceuticals Inc (NASDAQ: MACK) …
Smallcap Network · 7/14/2015
Stock analysts at HC Wainright initiated coverage on shares of Spectrum Pharmaceuticals (NASDAQ:SPPI) in a report issued on Monday, Market Beat.com reports. The firm set a “buy” rating and a $10.00 price target on the biotechnology company’s …
wkrb13.com · 6/30/2015
Spectrum Pharmaceuticals (NASDAQ:SPPI) was upgraded by Zacks from a “strong sell” rating to a “hold” rating in a research note issued on Tuesday, AnalystRatingsNetwork.com reports. According to Zacks, “Spectrum Pharmaceuticals, Inc. is ...
Ticker Report · 7/14/2015
Spectrum Pharmaceuticals, Inc. (SPPI) was a big mover last session, as its shares rose over 10% on the day. The upside came on the back of an encouraging announcement by an activist that the company could fetch more than $7.95 a share in a sale.
Yahoo Finance · 5/13/2015
SPPI)’s most prominent drug, Fusilev, to generic competition, the company handed out $2 million in bonuses and salary increments to its top four executives. This came from a company whose stock has slumped by 50% over the last three years, while ...
INSIDER MONKEY · 6/4/2015
2015 is unlikely to bring the hopes and dreams of a stock recovery that Spectrum Pharmaceuticals (NASDAQ:SPPI) investors so anxiously desire. In late December, Spectrum filed a new drug application for a product that has created quite a bit of buzz …
Seeking Alpha · 3/10/2015
We believe long-term investors should be buyers of Spectrum (ticker: SPPI SPPI 2.1418020679468244% Spectrum Pharmaceuticals ... we believe the current stock price offers an attractive opportunity to buy what we view as a development-stage biotech …
Barron's · 4/3/2015